Intra-Cellular Therapies
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Intra-Cellular Therapies sits in the top decile of US sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count).
Intra-Cellular Therapies: 37 sponsored US clinical trials, 14 recruiting.
Intra-Cellular Therapies sponsors 37 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 22 completed. 18 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 4 trials.
Top-decile sponsor footprint
Intra-Cellular Therapies ranks in the top decile of sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
37 total, page 1 of 1
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
NCT06706674
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
NCT06462612
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
NCT06462586
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
NCT06557902
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
NCT06299410
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
NCT05766813
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
NCT06627413
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
NCT05732194
A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects
NCT05470101
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05061719
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05061706
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT04985942
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
NCT04959032
Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
NCT04779177
Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia
NCT04709224
Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
NCT04934124
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
NCT04285515
Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement
NCT03489772
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure
NCT03387215
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
NCT03249376
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
NCT03257046
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
NCT02817906
Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
NCT02600507
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
NCT02600494
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
NCT02469155
A Trial to Assess the Antipsychotic Efficacy of ITI-007
NCT02282761
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
NCT02288845
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
NCT02078310
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
NCT01499563
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 7 |
| Phase 3 | 18 |
Therapeutic Areas
What is open in the Intra-Cellular Therapies pipeline
14 recruiting of 37 indexed (38% open); 22 completed (59%).
Phase mix: 18 late (III/IV) vs 19 early (I/II) (balanced across stages).
Top condition: Healthy Volunteers (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Intra-Cellular Therapies: open-pipeline peers nationwide
Peers matched on 37 registered trials and 38% open enrollment, not the therapeutic-area sidebar.
Intra-Cellular Therapies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 37 trials (± recruiting share)
- Appalachian State University · 37 trials · 3% recruiting
- Bracco Diagnostics · 37 trials · 3% recruiting
- Carnegie Mellon University · 37 trials · 11% recruiting
- Cutera · 37 trials · 0% recruiting
Sponsors near 38% open enrollment (± trial volume)
- Children's National Research Institute · 38% recruiting · 92 trials
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 38% recruiting · 8 trials
- American Thrombosis and Hemostasis Network · 38% recruiting · 8 trials
- AskBio · 38% recruiting · 8 trials
Related
What to do with this Intra-Cellular Therapies page
37 registered trials is a research-attention snapshot, not an endorsement of Intra-Cellular Therapies or any single study.
- 14 of Intra-Cellular Therapies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Intra-Cellular Therapies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Intra-Cellular Therapies pipeline card: 37 registered trials from official public datasets.Report a data error.